Romano Brothers & Co’s Biogen BIIB Stock Holding History

Romano Brothers & Co’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-445	Closed	-$123K	–	368
2022 Q4	$123K	Buy	+445	New	+$126K	0.02%	348

Other funds holding BIIB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Romano Brothers & Co's BIIB Position: Q1 2023 in Review

Romano Brothers & Co sold out of Biogen (BIIB) in Q1 2023, closing a stake of 445 shares — an estimated $123K sold.

Romano Brothers & Co first reported a position in BIIB in Q4 2022 and held it in 1 quarter. The position peaked at $123K in Q4 2022. 1,001 funds tracked by Wall St. Rank hold BIIB as of Q1 2023.

Romano Brothers & Co reported no remaining Biogen position as of Q1 2023 after selling out during the quarter.
Romano Brothers & Co sold 445 Biogen shares in Q1 2023, an estimated $123K.
Romano Brothers & Co first reported a position in Biogen in Q4 2022 and held it in 1 quarter.
Romano Brothers & Co's Biogen position peaked at $123K in Q4 2022.
1,001 funds tracked by Wall St. Rank held Biogen as of Q1 2023.

Based on Romano Brothers & Co's 13F filing for Q1 2023, filed 13 Apr 2023.